[
  {
    "ts": null,
    "headline": "Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?",
    "summary": "Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.",
    "url": "https://finnhub.io/api/news?id=34d301c310900fa99310d314f9e6661616a6ab8a221e7d329c0f9165141be506",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763739000,
      "headline": "Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?",
      "id": 137572058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.",
      "url": "https://finnhub.io/api/news?id=34d301c310900fa99310d314f9e6661616a6ab8a221e7d329c0f9165141be506"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI",
    "summary": "LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.",
    "url": "https://finnhub.io/api/news?id=f4f5567a3ba6747522fe9272e3686fcdc1b0c7fef74e048e2a49bcf1bbbc9336",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763738340,
      "headline": "Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI",
      "id": 137571876,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.",
      "url": "https://finnhub.io/api/news?id=f4f5567a3ba6747522fe9272e3686fcdc1b0c7fef74e048e2a49bcf1bbbc9336"
    }
  },
  {
    "ts": null,
    "headline": "Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth",
    "summary": "ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.",
    "url": "https://finnhub.io/api/news?id=3afe8c48a0d79d6930f22ce64ea0d8cd04b14436f7db205f87c6063d0fb24150",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763733960,
      "headline": "Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth",
      "id": 137572060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.",
      "url": "https://finnhub.io/api/news?id=3afe8c48a0d79d6930f22ce64ea0d8cd04b14436f7db205f87c6063d0fb24150"
    }
  }
]